

Primary Prevention of Anthracycline-induced Cardiotoxicity with L-Carnitine in patients with breast Cancer (PPACC): pilot study

Submission date 02/04/2007	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 02/04/2007	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 12/02/2019	Condition category Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Benjamin Chow

Contact details
University of Ottawa Heart Institute
40 Ruskin Street
Ottawa
Ontario
Canada
K1Y 4W7
+1 613 761 4044
bchow@ottawaheart.ca

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number
NCT00247975

Secondary identifying numbers

MCT-78520

Study information

Scientific Title

Primary Prevention of Anthracycline-induced Cardiotoxicity with L-Carnitine in patients with breast Cancer (PPACC): pilot study

Acronym

PPACC

Study objectives

Primary hypothesis:

Compared to placebo, L-carnitine will reduce the cytotoxic effects of epirubicin on Left Ventricular Ejection Fraction (LVEF).

Secondary hypothesis:

Compared to placebo, patients treated with L-carnitine will have:

1. Smaller increases in LV end-systolic and end-diastolic volumes
2. Lower serum Troponin T (TnT) and Brain Natriuretic Peptide (BNP) levels
3. A reduced incidence of "anthracycline-induced cardiotoxicity"
4. Higher serum L-carnitine levels
5. Similar occurrence of adverse events (breast cancer response, seizures, etc.,)

We will also test the hypothesis that TnT, BNP, serum L-carnitine levels correlate with changes in LVEF, end systolic volume, and end diastolic volume.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approval received from the Human Research Ethics Board of University of Ottawa Heart Institute (Canada) on the 7th October 2005 (ref: UOHI 2006-124).

Study design

One centre, two arm, double blind, randomised, parallel group, placebo controlled trial, with study participant, study investigator, caregiver, outcome assessor and data-analyst blinding

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Breast Cancer

Interventions

Experimental group: L-Carnitine therapy plus chemotherapy (FEC-100):

Oral L-carnitine (3 grams daily) for three days prior to chemotherapy, 1 gram of intravenous L-carnitine (5 cc over five minutes, prior to chemotherapy) on the day of chemotherapy and oral L-carnitine (3 grams daily) for three days after chemotherapy.

Control group: placebo (matching L-Carnitine therapy) plus chemotherapy (FEC-100):

Oral placebo for three days prior to chemotherapy, intravenous placebo (5 cc over five minutes, prior to chemotherapy) on the day of chemotherapy and oral placebo for three days after chemotherapy.

Contact for public queries:

Jason King

University of Ottawa Heart Institute

40 Ruskin Street

Ottawa, Ontario

Canada

K1Y 4W7

Tel: +1 613 761 9703

Fax: +1 613 761 4596

Email: jking@ottawaheart.ca

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

L-Carnitine, 5-fluorouracil, epirubicin, and cyclophosphamide

Primary outcome measure

1. Change in Ejection Fraction (EF) (measure by Radionuclide Angiocardiology [RNA]) at one year, compared to the patient's own baseline. LVEF is used clinically to assess patients' eligibility for continued chemotherapy.

Secondary outcome measures

1. LV end-systolic and end-diastolic volumes (RNA)
2. LV diastolic dysfunction (Echocardiography [ECHO])
3. Serum TnT and BNP measured with each cycle of chemotherapy (immediately prior to and three days after chemotherapy)
4. Composite outcome of: cardiac death, clinical congestive heart failure, reduction in EF requiring termination of anthracycline therapy (LVEF reduction greater than or equal to 10% and LVEF less than 50%), dexrazoxane use or "anthracycline-induced cardiotoxicity"
5. Adverse events (e.g. chemotherapy efficacy, seizures, nausea, diarrhoea)

A secondary analysis of correlation of serum biomarkers (serum L-Carnitine levels, serum TnT, BNP) with surrogate markers of cardiotoxicity (LVEF, LV volumes and diastolic dysfunction) will also be performed.

Overall study start date

01/11/2005

Completion date

31/10/2008

Eligibility

Key inclusion criteria

1. Breast cancer patients (stages I, II, III) eligible for adjuvant epirubicin chemotherapy (5-Fluorouracil, Epirubicin, and Cyclophosphamide [FEC]-100)
2. Eastern Cooperative Oncology Group (ECOG) performance status equals zero to two
3. Informed consent

Amended as of 20/04/2007:

1. Women, aged greater than or equal to 18 years
2. Breast cancer patients (stages I, II, III) eligible for adjuvant epirubicin chemotherapy (FEC100)
3. HER2 negative breast cancer by immunohistochemistry (IHC3+) and/or fluorescent in-situ hybridization
4. Eastern Cooperative Oncology Group (ECOG) performance status equal to zero to two
5. Ability to understand and the willingness to sign a written informed consent document
6. Women of child-bearing potential must agree to use adequate contraception prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately

Participant type(s)

Patient

Age group

Not Specified

Lower age limit

18 Years

Sex

Not Specified

Target number of participants

128 (Amended to 144 as of 20/04/2007)

Key exclusion criteria

1. Resting LVEF less than 50%
2. Previous anthracycline therapy or contraindication to anthracycline
3. Contraindication to L-carnitine therapy
4. Dexrazoxane therapy at the time of enrolment

5. Participation in another randomised clinical trial
6. Significant cardiac disease (previous myocardial infarction, congestive heart failure, haemodynamically significant valvular heart disease)
7. Medication that may affect LV function or symptoms of heart failure (beta-blockers, amiodarone, Angiotensin Converting Enzyme [ACE]-inhibitors, calcium channel blockers, digoxin)
8. Aged less than 18 years or inability to give informed consent
9. Evidence of metastatic breast cancer
10. Patients unable to participate in a study requiring long term follow up
11. Abnormal baseline: Complete blood count (Haemoglobin [Hb] less than 100 mg/L, Platelets [Plt] less than $100 \times 10^9/L$, White Blood Cells [WBC] less than $4 \times 10^9/L$), creatinine, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) or bilirubin greater than 1.5 times the upper limit of normal

Amended as of 20/04/2007:

1. Resting LVEF less than 50%
2. Previous anthracycline therapy or contraindication to anthracycline
3. Contraindication to L-carnitine therapy
4. Dexrazoxane therapy at the time of enrollment
5. Participation in another randomised clinical trial
6. Significant cardiac disease (previous myocardial infarction, congestive heart failure, hemodynamically significant valvular heart disease)
7. Medication that may affect LV function or symptoms of heart failure (b-blockers, amiodarone, ACE-inhibitors, calcium channel blockers, digoxin)
8. Pregnant or lactating women
9. Evidence of metastatic breast cancer.
10. Patients unable to participate in a study requiring long term follow up
11. Abnormal baseline: Complete blood count (Hb less than 100 mg/L, Plt less than $100 \times 10^9/L$, WBC less than $4 \times 10^9/L$), Creatinine AST, ALT or Bilirubin greater than or equal to 1.5 the upper limit of normal

Date of first enrolment

01/11/2005

Date of final enrolment

31/10/2008

Locations

Countries of recruitment

Canada

Study participating centre

University of Ottawa Heart Institute

Ontario

Canada

K1Y 4W7

Sponsor information

Organisation

University of Ottawa Heart Institute (Institut de cardiologie de l'Université d'Ottawa) (Canada)

Sponsor details

40 Ruskin Street
Ottawa
Ontario
Canada
K1Y 4W7

Sponsor type

University/education

Website

<http://www.ottawaheart.ca/UOHI/>

ROR

<https://ror.org/03c4mmv16>

Funder(s)

Funder type

Research organisation

Funder Name

Canadian Institutes of Health Research (CIHR) (Canada) - <http://www.cihr-irsc.gc.ca/> (ref: MCT-78520)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration